NCT00479427View on ClinicalTrials.gov

A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis

PHASE2CompletedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

July 6, 2007

Primary Completion Date

October 9, 2007

Study Completion Date

October 9, 2007

Conditions

Osteoarthritis

Interventions

DRUG

GW842166

100 mg once daily

DRUG

Placebo

once daily

Trial Locations (1)

W12 0NN

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY